Chloe Linton, NP
Acute Care · Greenville, NCNPI 1407510563
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.1% of the total across 99 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations.
Across 99 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$457
- AstraZeneca$234
- Johnson & Johnson$201
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$185
- Astellas Pharma US Inc$146
- Incyte Corporation$92
- plus $709 from 17 others
What the payments were for
- Food & beverage$1,92495%
- Education$1005%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 24 | $457 |
| AstraZeneca(2 entities) | 11 | $234 |
| Johnson & Johnson(2 entities) | 10 | $201 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $185 |
| Astellas Pharma US Inc | 3 | $146 |
| Incyte Corporation | 5 | $92 |
| Pfizer | 5 | $86 |
| Boehringer Ingelheim | 4 | $80 |
| Exelixis Inc. | 4 | $71 |
| Melinta Therapeutics, LLC | 3 | $67 |
| Smith+Nephew | 3 | $52 |
| AbbVie | 3 | $51 |
| Amgen | 2 | $40 |
| Novartis | 3 | $40 |
| Scpharmaceuticals Inc. | 1 | $33 |
| Stryker | 1 | $30 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $29 |
| Inari Medical, Inc. | 1 | $28 |
| Legend Biotech USA Inc. | 1 | $24 |
| Eisai Inc. | 1 | $22 |
| Gilead | 1 | $20 |
| Beone Medicines USA, Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $18 |
How this compares
$2,024 in reported general payments places this provider in the 85th percentile of 312 acute care providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $87 |
| Oxycodone Hcl | 21 | $80 |
Paid to pharmacies, not to this prescriber.
Other acute care in Greenville
- Benjamin HocuttGreenville$25K
- Shalaila SalazarGreenville$6K
- Ashley SchneiderGreenville$6K
- Heather DayGreenville$5K
- Cora KearleyGreenville$3K
- Jennifer MurphyGreenville$3K
- Kelly KittleGreenville$2K
- Melissa FulmerGreenville$2K
- Matthew KuhnPinehurst$16K
- Robin TruppApex$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.